3B Blackbio Dx Board of Directors
Get the latest insights into the leadership at 3B Blackbio Dx. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Dhirendra Dubey | Chairman & Managing Director |
| Mr. N K Dubey | Whole Time Director |
| CA. Shabbar Husain | Independent Director |
| Mr. Abdul Moin Khan | Independent Director |
| Mrs. Mithala Dubey | Director |
| Mr. Harihar Prasad Thapak | Independent Director |
3B Blackbio Dx Share price
3BBLACKBIO
1432.75
16.50 (-1.14%)Last updated on 4 Sep, 2025 | 15:41 IST
BUYSELL
Today's High
1500.00
Today's Low
1420.05
52 Week Low
1253.80
52 Week High
2350.00
The current prices are delayed, login to your account for live prices
Login3B Blackbio Dx FAQs
The board at 3B Blackbio Dx consists of experienced professionals, including Mr. Dhirendra Dubey , Mr. N K Dubey , and others, overseeing the company’s strategic and corporate governance.
Directors at 3B Blackbio Dx are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Dhirendra Dubey is the current chairman at 3B Blackbio Dx.
Executive directors at 3B Blackbio Dx are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, 3B Blackbio Dx adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At 3B Blackbio Dx, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.